Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Similar Items

• Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
  by: Ari Raphael, et al.
  Published: (2022-09-01)
• Alpelisib as a new treatment option for patients with the PIK3CA mutation. The effectiveness and tolerability of therapy on the example of a clinical case
  by: Е. I. Kovalenko, et al.
  Published: (2021-06-01)
• Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice
  by: D. A. Filonenko, et al.
  Published: (2021-12-01)
• Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
  by: Chang DY, et al.
  Published: (2021-03-01)
• Anticancer effects of alpelisib on PIK3CA-mutated canine mammary tumor cell lines
  by: Jiah Yeom, et al.
  Published: (2023-11-01)